Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gottlieb Becomes US FDA Commissioner With Immediate Issues Pending

Executive Summary

Senate confirmation includes fewest supporting votes for any candidate ever as agency tackles budget, user fees and other issues.


Related Content

Gottlieb Closing In On Confirmation Despite Senate Concern On Opioids
Ostroff: Administration Coming Up To Speed On Planned FDA Guidances
US FDA Gains Budget Increase In FY 2017… And Not Through Fees
First Draft FDA User Fee Bill Is Squeaky Clean
Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse
Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?
Trump's Budget Outline Threatens User Fee Agreements
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure
Califf Maintains Desire To Stay At FDA, But Would Either Presidential Candidate Keep Him?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts